Literature DB >> 22266332

Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men.

Katya B Rubinow1, Chongren Tang, Andrew N Hoofnagle, Christin N Snyder, John K Amory, Jay W Heinecke, Stephanie T Page.   

Abstract

Exogenous androgens can lower HDL-cholesterol (HDL-C) concentrations, yet men with low serum testosterone have elevated rates of cardiovascular disease (CVD). HDL function may better predict CVD risk than absolute HDL-C quantity. We evaluated the acute effects of medical castration in men on HDL-C, cholesterol efflux capacity and HDL protein composition. Twenty-one healthy men, ages 18-55, received the GnRH antagonist acyline and one of the following for 28days: Group 1: placebo, Group 2: transdermal testosterone gel and placebo, Group 3: transdermal testosterone gel and an aromatase inhibitor. Sex steroids, fasting lipids, and cholesterol efflux to apoB-depleted serum were measured in all subjects. The HDL proteome was assessed in Group 1 subjects only. In Group 1, serum testosterone concentrations were reduced by >95%, and HDL-C and cholesterol efflux capacity increased (p=0.02 and p=0.03 vs. baseline, respectively). HDL-associated clusterin increased significantly with sex steroid withdrawal (p=0.007 vs. baseline). Testosterone withdrawal in young, healthy men increases HDL-C and cholesterol efflux capacity. Moreover, sex steroid deprivation changes HDL protein composition. Further investigation of the effects of sex steroids on HDL composition and function may help resolve the apparently conflicting data regarding testosterone, HDL-C, and CVD risk. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22266332      PMCID: PMC3304018          DOI: 10.1016/j.steroids.2012.01.002

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  41 in total

1.  High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide.

Authors:  Masashi Suzuki; David K Pritchard; Lev Becker; Andrew N Hoofnagle; Natsuko Tanimura; Theo K Bammler; Richard P Beyer; Roger Bumgarner; Tomas Vaisar; Maria C de Beer; Frederick C de Beer; Kensuke Miyake; John F Oram; Jay W Heinecke
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

Review 2.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

3.  Serum cholesterol efflux potential in postmenopausal monkeys treated with tibolone or conjugated estrogens.

Authors:  Tomi S Mikkola; Mary S Anthony; Thomas B Clarkson; Richard W St Clair
Journal:  Metabolism       Date:  2002-04       Impact factor: 8.694

Review 4.  The metabolic role of lecithin: cholesterol acyltransferase: perspectives from pathology.

Authors:  J A Glomset
Journal:  Adv Lipid Res       Date:  1973

5.  Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia.

Authors:  Andrew N Hoofnagle; Mingyuan Wu; Albina K Gosmanova; Jessica O Becker; Ellen M Wijsman; John D Brunzell; Steven E Kahn; Robert H Knopp; Timothy J Lyons; Jay W Heinecke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-09-16       Impact factor: 8.311

6.  The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.

Authors: 
Journal:  Am Heart J       Date:  2011-02-02       Impact factor: 4.749

7.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

8.  Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men.

Authors:  C J Bagatell; R H Knopp; J E Rivier; W J Bremner
Journal:  J Clin Endocrinol Metab       Date:  1994-04       Impact factor: 5.958

9.  Protection against atherogenesis in mice mediated by human apolipoprotein A-IV.

Authors:  N Duverger; G Tremp; J M Caillaud; F Emmanuel; G Castro; J C Fruchart; A Steinmetz; P Denèfle
Journal:  Science       Date:  1996-08-16       Impact factor: 47.728

10.  The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis.

Authors:  Daniel J Rader; Eric T Alexander; Ginny L Weibel; Jeffrey Billheimer; George H Rothblat
Journal:  J Lipid Res       Date:  2008-12-08       Impact factor: 5.922

View more
  8 in total

1.  Sex steroids mediate discrete effects on HDL cholesterol efflux capacity and particle concentration in healthy men.

Authors:  Katya B Rubinow; Tomas Vaisar; Jing H Chao; Jay W Heinecke; Stephanie T Page
Journal:  J Clin Lipidol       Date:  2018-04-30       Impact factor: 4.766

Review 2.  HDL and cholesterol: life after the divorce?

Authors:  Kasey C Vickers; Alan T Remaley
Journal:  J Lipid Res       Date:  2013-03-19       Impact factor: 5.922

Review 3.  Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond.

Authors:  Amy S Shah; Lirong Tan; Jason Lu Long; W Sean Davidson
Journal:  J Lipid Res       Date:  2013-02-24       Impact factor: 5.922

4.  Perimenopausal transdermal estradiol replacement reduces serum HDL cholesterol efflux capacity but improves cardiovascular risk factors.

Authors:  Tomas Vaisar; Jennifer L Gordon; Jake Wimberger; Jay W Heinecke; Alan L Hinderliter; David R Rubinow; Susan S Girdler; Katya B Rubinow
Journal:  J Clin Lipidol       Date:  2020-11-24       Impact factor: 4.766

5.  Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity.

Authors:  Katya B Rubinow; Tomas Vaisar; Chongren Tang; Alvin M Matsumoto; Jay W Heinecke; Stephanie T Page
Journal:  J Lipid Res       Date:  2012-04-13       Impact factor: 5.922

6.  Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study.

Authors:  A M Traish; A Haider; G Doros; F Saad
Journal:  Int J Clin Pract       Date:  2013-10-15       Impact factor: 2.503

7.  Integrated molecular landscape of Parkinson's disease.

Authors:  J E Visser; G Poelmans; C J H M Klemann; G J M Martens; M Sharma; M B Martens; O Isacson; T Gasser
Journal:  NPJ Parkinsons Dis       Date:  2017-04-10

Review 8.  High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives.

Authors:  Maria Pia Adorni; Nicoletta Ronda; Franco Bernini; Francesca Zimetti
Journal:  Cells       Date:  2021-03-05       Impact factor: 7.666

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.